A growth-factor analogue, not a GH-releasing peptide
IGF-1 LR3 is a modified analogue of insulin-like growth factor I. It belongs in an endocrine research discussion, but it should not be grouped mechanistically with peptides that stimulate GH secretion. An intervention at an IGF-related signaling system is a different molecular question from stimulation of pituitary hormone release.
Why the LR3 identity matters
The modified analogue is used in laboratory research where interactions with IGF-binding proteins are relevant. The molecular changes are part of the experiment, not a cosmetic naming difference. A publication that tested native IGF-I cannot be assumed to establish the same result for LR3, and a result for LR3 should not be silently relabeled as evidence for all IGF-I preparations.
What a cell-study comparison tells us
The linked primary study compared IGF-I and Long-R3-IGF-I in myogenic cell systems while investigating the influence of IGF-binding protein-3. This is evidence about proliferation, differentiation and binding-protein context in a laboratory model. It does not establish that administering LR3 to a person increases useful muscle function or improves health.
Why binding conditions are important
A culture experiment has a defined medium, cell type and exposure period. Binding proteins and other components can influence how a ligand behaves in that system. When comparing experiments, ask whether those conditions were aligned. A larger response in one preparation may reflect the model or assay conditions and should not be translated into a general claim that one compound is superior.
Growth signals and beneficial outcomes are not synonyms
Proliferation means that cells multiplied under the measured conditions. A clinical claim requires a different level of evidence: which tissue changed, whether function improved, how adverse effects were monitored and whether the result persisted. A laboratory growth signal should not be marketed as a complete account of the consequences of an intervention.
Distinguishing research materials from medicines
The FDA has named IGF1-LR3 in historical compounding enforcement correspondence. That document is a dated record of a particular inspection and regulatory context, not a current global authorization database. This dossier does not claim that a substance sold as LR3 is equivalent to a regulated IGF-I product. Identity, formulation and authorization must each be checked separately.
